Atossa Therapeutics
ATOS
54 hedge funds and large institutions have $11.9M invested in Atossa Therapeutics in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 6 closing their positions.
850% more call options, than puts
Call options by funds: $779K | Put options by funds: $82K
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
4% more funds holding
Funds holding: 52 → 54 (+2)
0.01% more ownership
Funds ownership: 0.84% → 0.86% (+0.01%)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
41% less capital invested
Capital invested by funds: $20.2M → $11.9M (-$8.26M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$163K |
| 2 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$129K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$124K |
| 4 |
Two Sigma Investments
New York
|
+$112K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$54.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$273K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$120K |
| 3 |
Millennium Management
New York
|
-$74.2K |
| 4 |
Jane Street
New York
|
-$59.6K |
| 5 |
Morgan Stanley
New York
|
-$44.6K |
ATOS Hedge Fund Activity: Q3 2023 in Review
54 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q3 2023, worth a combined $11.9M — down 41% from $20.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ATOS positions and 6 closed out — a net gain of 2 holders — while 11 added to existing stakes and 15 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $163K. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $273K sold.
- 54 institutional investors held Atossa Therapeutics (ATOS) as of Q3 2023, up from 52 in Q2 2023.
- Funds reported $11.9M of Atossa Therapeutics stock for Q3 2023, down 41% quarter-over-quarter.
- 8 funds opened new Atossa Therapeutics positions in Q3 2023 and 6 closed out, a net change of +2 holders.
- The largest Atossa Therapeutics buyer in Q3 2023 was Renaissance Technologies, an estimated $163K added.
- The largest Atossa Therapeutics seller in Q3 2023 was D.E. Shaw & Co, an estimated $273K sold.
Based on aggregated 13F filings for Q3 2023.